A retrospective single-center study comparing PD-1 inhibitors combined with nab-paclitaxel plus gemcitabine (AG) chemotherapy versus AG as the first-line treatment of advanced pancreatic cancer reported that PD-1+AG could improve the OS of patients with KRAS/TP53 co-mutations [72]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.